Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting

被引:14
作者
Censarek, Petra [2 ]
Steger, Gerhard [3 ]
Paolini, Carla [2 ]
Hohlfeld, Thomas [2 ]
Grosser, Tilo [4 ,5 ]
Zimmermann, Norbert [6 ]
Fleckenstein, Diana [1 ]
Schroer, Karsten [2 ]
Weber, Artur-Aron [1 ]
机构
[1] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany
[2] Univ Klinikum Duesseldorf, Inst Pharmakol & Klin Pharmakol, Dusseldorf, Germany
[3] Univ Dusseldorf, Inst Phys Biol, D-4000 Dusseldorf, Germany
[4] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA
[6] Bundesinst Arzneimittel & Med Prod, Bonn, Germany
关键词
platelet COX-2; COX-2a; aspirin; thromboxane; CABG; qPCR;
D O I
10.1160/TH07-05-0346
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, we cloned from platelet mRNA a novel cyclooxygenase (COX)-2 splice variant, designated COX-2a, which is characterized by a partial deletion of exon 5.Preliminary studies of mRNA distribution of COX-2 isoforms in platelets from coronary artery bypass grafting (CABG) patients showed a variable increase in COX-2a mRNA expression after cardiac surgery.Thus, we assessed whether this variant may play a functional role in these patients.We report a marked (about 200-fold) increase in the expression of COX-2a mRNA after CABG. Evidence is presented that ribosomal frame-shifting may correct the coding sequence resulting in the expression of a full-length COX-2a protein. In addition, a reading frame-corrected COX-2a mutant (COX-2a Delta G) was generated by site-directed mutagenesis and expressed in COS-7 cells using an adenoviral expression system. However, COX-2a protein was not active in terms of prostaglandin formation. Thus, alternative mRNA splicing might represent an intriguing posttranscriptional mechanism to oppose a transcriptional activation of the COX-2 gene. Evolutionary, this mechanism may prevent COX-2-dependent thromboxane synthesis in the platelet, which would potentiate the likelihood of thrombosis; pharmacologically, this mechanism would prevent an aspirin-insensitive pathway of thromboxane formation.
引用
收藏
页码:1309 / 1315
页数:7
相关论文
共 39 条
[1]   LOW ACTIVITY OF BETA-GALACTOSIDASE IN FRAMESHIFT MUTANTS OF ESCHERICHIA-COLI [J].
ATKINS, JF ;
ELSEVIERS, D ;
GORINI, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1972, 69 (05) :1192-+
[2]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[3]   Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting [J].
Censarek, P ;
Freidel, K ;
Udelhoven, M ;
Ku, SJ ;
Hohlfeld, T ;
Meyer-Kirchrath, J ;
Schrör, K ;
Weber, AA .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (05) :925-928
[4]   Human cyclooxygenase-1b is not the elusive target of acetaminophen [J].
Censarek, Petra ;
Freidel, Kerstin ;
Hohfeld, Thomas ;
Schroer, Karsten ;
Weber, Artur-Aron .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) :50-53
[5]   COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression [J].
Chandrasekharan, NV ;
Dai, H ;
Roos, KLT ;
Evanson, NK ;
Tomsik, J ;
Elton, TS ;
Simmons, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13926-13931
[6]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541
[7]  
DIMINNO G, 1983, BLOOD, V61, P1081
[8]   MECHANISMS OF PLATELET ACTIVATION - THROMBOXANE-A2 AS AN AMPLIFYING SIGNAL FOR OTHER AGONISTS [J].
FITZGERALD, GA .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (07) :B11-B15
[9]   Structure, stability and function of RNA pseudoknots involved in stimulating ribosomal frameshifting [J].
Giedroc, DP ;
Theimer, CA ;
Nixon, PL .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 298 (02) :167-185
[10]   Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].
Grosser, T ;
Fries, S ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15